僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Etrolizumab （rhuMAb Beta7） is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease （IBD）